Quantcast

Latest Typical antipsychotic Stories

2014-07-14 08:26:29

Submission based on first head-to-head study vs. oral treatments in real world context TITUSVILLE, N.J., July 14, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking a label change that, if approved, would include new data showing significantly delayed time to relapse in patients prescribed once-monthly atypical long-acting antipsychotic INVEGA(®)...

2014-06-20 23:09:40

The San Diego personal injury lawyers of The Law Office of Melinda J. Helbock, A.P.C. are investigating potential lawsuits on behalf of boys and men who developed gynecomastia after using Risperdal. San Diego, California (PRWEB) June 20, 2014 According to a recent study, use of atypical antipsychotics in children is increasing in Australia and other countries. According to the study, more than 12,600 children under the age 19 are using antipsychotics, and the most commonly prescribed drug...

2014-05-13 08:33:18

New submission based on positive data from a 15-month schizoaffective relapse prevention study TITUSVILLE, N.J., May 13, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., today announced the submission of supplemental New Drug Applications (sNDAs) for once-monthly atypical long-acting antipsychotic INVEGA(®) SUSTENNA(®) (paliperidone palmitate) to the U.S. Food and Drug Administration (FDA) for approval to treat schizoaffective disorder as either monotherapy or adjunctive...

2014-05-07 23:03:04

The Firm is representing Risperdal lawsuit clients who allegedly developed gynecomastia (male breast growth) due to their use of the atypical antipsychotic medication. New York, NY (PRWEB) May 07, 2014 As Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that a group of medical researchers is seeking physician participation in a national registry that tracks the use of atypical antipsychotic medications in pregnant...

2014-05-06 16:32:22

Demonstrated significant efficacy in manic and depressive mood symptoms and psychosis, and improved patient functioning TITUSVILLE, N.J., May 6, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., today announced the results of the company's schizoaffective relapse prevention study of once-monthly atypical long-acting antipsychotic INVEGA(®) SUSTENNA(® )(paliperidone palmitate). The trial found INVEGA(®) SUSTENNA(®) met its primary endpoint of delayed time to and reduced risk of...

2014-05-05 08:29:33

First prospective, randomized clinical trial to reflect context of "real world" issues in treating schizophrenia, including recent incarceration and substance abuse TITUSVILLE, N.J., May 5, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., today announced the results of its landmark PRIDE (Paliperidone Palmitate Research In Demonstrating Effectiveness) trial. PRIDE is the first prospective, randomized clinical trial to compare schizophrenia medications within the context of many...

2014-04-22 08:34:04

TITUSVILLE, N.J., April 22, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., and Janssen Research and Development, LLC, both members of the Johnson & Johnson Family of Companies, announced that several posters related to the company's work in mental health will be featured at the 167(th) Annual Meeting of the American Psychiatric Association (APA) in New York City May 3 to 7. The posters are: -- Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE):...

2014-03-20 08:29:49

Independent Data Monitoring Committee Recommends Halting Trial and Unblinding Data Based on Treatment Efficacy TITUSVILLE, N.J., March 20, 2014 /PRNewswire/ -- Janssen Research & Development, LLC announced today that following an Independent Data Monitoring Committee (IDMC) recommendation based on positive efficacy, it has halted early a Phase 3 clinical study of paliperidone palmitate 3-month formulation, an investigational treatment for symptoms of schizophrenia in adults. "We are...

2014-03-03 08:31:55

ADASUVE is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults MOUNTAIN VIEW, Calif., March 3, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the U.S. commercial launch of ADASUVE(®) (loxapine) inhalation powder 10mg by its commercial partner, Teva Pharmaceutical Industries Ltd., (NYSE: TEVA). ADASUVE is the first and only orally inhaled medicine for the acute...

2014-02-11 16:25:38

First liquid formulation clozapine for treatment-resistant schizophrenia DUBLIN, Feb. 11, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced U.S. commercial availability of Versacloz(TM) (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder. "We are pleased to offer patients with...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related